CAPR Deramiocel: Upper-Limb Claim Resets PDUFA Clock

Update August 27, 2026: CAPR closed at $9.36 on August 26 (Polygon), up 48.8% from the $6.29 August 21 close. Oppenheimer upgraded the stock on August 25 following the FDA’s confirmation that deramiocel’s PDUFA is extended to November 22 (upper-limb-only claim). The stock continues to re-rate off the August 13 pivot and the amendment-based extension.

Update August 25, 2026: The FDA confirmed on August 24 that it extended deramiocel’s PDUFA target action date from August 22 to November 22, 2026, classifying Capricor’s upper-limb-only BLA amendment as a major amendment (a three-month extension). The agency cited the significant unmet need in DMD and accepted the 24-month HOPE-3 open-label extension data for review. See the Capricor press release.

Capricor Therapeutics (CAPR) is retreating to its one strong data point. In its August 13 second-quarter earnings release, the company said it will submit a BLA amendment that narrows deramiocel’s proposed indication from DMD-associated cardiomyopathy to upper-limb dysfunction only, the endpoint where its HOPE-3 trial showed a statistically significant signal.

The FDA has now confirmed it will extend the August 22 PDUFA target action date to November 22, 2026, classifying the amendment as major. CAPR closed at $6.29 on August 21 (Polygon), up 63% from its July 31 close of $3.85 after surging 67% after-hours on August 13 when the pivot was announced.

The strategic retreat follows a brutal July 29 advisory committee, where the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that HOPE-3 did not provide substantial evidence of effectiveness for the cardiomyopathy claim. The panel centered on a statistical dispute: the FDA’s prespecified analysis showed a 0.66-point difference on the Performance of Upper Limb 2.0 (PUL 2.0) scale (95% CI, -0.45 to 1.77; p=0.24), while Capricor’s post-hoc analysis found p=0.029.

Deramiocel is an allogeneic cardiosphere-derived cell therapy. The narrowed filing would lean on the upper-limb endpoint plus 24-month open-label extension data and additional distal analyses. The BLA is already on its second review cycle after a July 2025 Complete Response Letter that the FDA later rescinded, and cardiomyopathy remains the leading cause of death in DMD, which is why Capricor originally sought the cardiac claim.

The key open question — whether the FDA would treat the amendment as major or non-major — has been answered. On August 24 the FDA classified the submission as a major amendment, extending the PDUFA by three months to November 22, 2026. That resets the clock predictably rather than leaving investors waiting on a non-major review with no fixed timeline.

There is also a bearish signal to weigh. STAT News reported on August 20 that the FDA is “heading for” rejection, describing Capricor’s submission of open-label extension data as “a stall tactic.” The original PDUFA was Saturday, August 22, though the FDA can act the Friday before or the Monday after. If the agency follows its advisory committee, a narrower upper-limb label is deramiocel’s best remaining shot, not a guaranteed one.

An upper-limb-only approval would also shrink the addressable market versus the cardiomyopathy claim the committee rejected, though it is the claim Capricor can actually defend on the data. For the full regulatory history, see the coverage of the 9-3 AdComm vote.

Source: Capricor Therapeutics Q2 2026 financial results press release